###### Key questions

What is already known about this subject?
=========================================

-   A low gradient is an independent predictor for mortality after transcatheter aortic valve implantation (TAVI) in severe aortic stenosis (AS).

-   Low-flow status has a poorer prognosis compared with the normal-flow status in low-gradient severe AS.

-   Studies have demonstrated that TAVI improves left ventricular function, and the improved left ventricular ejection fraction is associated with a good prognosis after TAVI.

-   However, in low-gradient severe AS, the type of low-flow status after TAVI that could influence prognosis has not been determined.

What does this study add?
=========================

-   The stroke volume index (SVi) of post-TAVI was an independent predictor of cardiovascular mortality (HR, 2.00; 95% CI 1.28 to 3.12; p=0.002) and hospitalisation for heart failure (HR, 1.35; 95% CI 1.03 to 1.76; p=0.028).

-   Post-TAVI SVi was a better predictor than pre-TAVI SVi for the estimation of cardiovascular mortality (0.61 (95% CI 0.56 to 0.65) vs 0.74 (95% CI 0.69 to 0.78), p=0.012).

How might this impact on clinical practice?
===========================================

-   Clinicians might consider evaluating SVi in patients with low-gradient severe AS before and after TAVI.

-   Strict follow-up guidelines should be adopted for patients with persisting low-flow status after TAVI.

Introduction {#s1}
============

Low-gradient severe aortic stenosis (AS), which is classified into classical low-flow, paradoxical low-flow and normal-flow low-gradient AS, is associated with a higher mortality rate even after transcatheter aortic valve implantation (TAVI) than high-gradient severe AS.[@R1] Our data also showed that a low-flow status was an independent predictor of cardiovascular mortality after TAVI.[@R3] However, it has not yet been examined whether post-TAVI flow status affects the prognosis, especially in patients with low-gradient severe AS. Therefore, we examined the prognostic value of the low-flow status using stroke volume index (SVi) before and after TAVI in patients with low-gradient severe AS.

Methods {#s2}
=======

Study population {#s2-1}
----------------

From October 2013 to July 2016, a total of 1613 consecutive patients with severe symptomatic AS who underwent TAVI with the Edwards Sapien XT, Edwards Sapien 3 (Edwards Lifesciences, Irvine, California) or Medtronic CoreValve prosthesis (Medtronic, Minneapolis, California) were enrolled prospectively in the Optimized Catheter Valvular Intervention-TAVI registry. The Optimized Catheter Valvular Intervention-TAVI registry is an ongoing Japanese prospective registry that aims to evaluate and observe the background and outcome in patients who undergo TAVI.[@R3] Fourteen institutions contributed to this registry. The inclusion criteria included the following: (1) presence of symptoms, (2) severe AS with class ≥II (classification by New York Heart Association) and (3) aortic valve area \<1.0 cm^2^ (or an effective orifice area index \<0.6 cm^2^/m^2^). A total of 448 patients with low-gradient severe AS (aortic valve mean gradient \<40 mm Hg) were included in this study. Of the 448 patients with low-gradient severe AS, 30 patients were excluded because of the deficits in preprocedure or postprocedure echocardiographic data for calculating SVi. Therefore, 418 symptomatic patients were finally included in the present study ([figure 1](#F1){ref-type="fig"}). There was no conversion to surgical aortic valve replacement among these 418 patients. All patients provided written informed consent before participating in this study.

![Patient selection process in the present study. The flow chart shows grouping of patients based on the 2014 American Heart Association/American College of Cardiology valvular disease guideline. AS, aortic stenosis; HG, high-gradient; LF, low-flow; LG, low-gradient; LVEF, left ventricular ejection fraction; MG, mean gradient; NF, normal-flow; SVi, stroke volume index.](openhrt-2018-000988f01){#F1}

Echocardiographic measurement {#s2-2}
-----------------------------

All patients in this study underwent standard two-dimensional B-mode and Doppler transthoracic echocardiography before and after the TAVI procedure. Conventional parameters were measured according to the European Association of Cardiovascular Imaging recommendations.[@R6] Post-TAVI echocardiography was performed during hospitalisation within a week after TAVI. Patients with low-gradient severe AS (418 patients) were divided into three groups according to pre-TAVI SVi and left ventricular ejection fraction values.[@R2] The three groups were formed as follows: classical low-flow low-gradient severe AS (left ventricular ejection fraction \<50%), paradoxical low-flow low-gradient severe AS (left ventricular ejection fraction ≥50% and pre-SVi \<35 mL/m[@R2]), and normal-flow low-gradient severe AS (left ventricular ejection fraction ≥50% and pre-SVi ≥35 mL/m[@R2]) ([figure 1](#F1){ref-type="fig"}). Patients' characteristics, echocardiographic parameters, as well as primary and secondary endpoints were compared among the three groups, and pre-TAVI with post-TAVI echocardiographic parameters were compared among each of the three groups.

Study endpoints {#s2-3}
---------------

The primary and secondary endpoints included cardiovascular mortality and hospitalisation for heart failure during follow-ups after TAVI. We defined cardiovascular mortality according to the criteria of the Valve Academic Research Consortium-2.[@R8] Hospitalisation for heart failure was defined as rehospitalisation after TAVI because of worsening chronic heart failure.

Statistical analysis {#s2-4}
--------------------

Statistical analyses were performed using SPSS V.24.0 and MedCalc V.17.5.5 software (MedCalc Software, Ostend, Belgium). Continuous variables were assessed for normal distribution using the Shapiro-Wilk test. Data are presented as mean±SD or median and IQR (25th--75th percentiles). We compared the differences in normally distributed data using one-way analysis of variance with subsequent Tukey's honest significant difference test, and the differences in non-normally distributed data using the Kruskal-Wallis test with Mann-Whitney test in the three groups. The Wilcoxon signed-rank test was used to compare pre-TAVI and post-TAVI echocardiographic data. Dichotomous variables are presented as numbers and percentages. χ^2^ test was used to compare categorical variables. Analyses with Cox proportional hazards regression models were performed to estimate predictors of cardiovascular mortality and hospitalisation for heart failure. Age, sex and clinically relevant echocardiographic variables, with reference to prior studies, were included in the multivariate models using a stepwise variable selection method in which variables were either entered or removed if p\<0.05 or p\>0.1, respectively.[@R1] The post-TAVI SVi threshold, which optimally predicted primary endpoints, was determined using the Youden Index of the receiver operating characteristic curves. A pairwise comparison of the area under the curve was used to analyse the relationship between cardiovascular mortality, pre-TAVI SVi and post-TAVI SVi.

Results {#s3}
=======

Patients' characteristics and echocardiographic parameters {#s3-1}
----------------------------------------------------------

Patients' characteristics and echocardiographic parameters are shown in [tables 1 and 2](#T1 T2){ref-type="table"}. The mean age of the patients was 84.0 years (IQR, 81.0--87.0) and 136 (32.5%) were men. The aortic valve mean gradient was 32.4 mm Hg (IQR, 28.0--36.0) at baseline, and the transcatheter heart valve mean gradient was 8.5 mm Hg (IQR, 7.0--11.0) after TAVI.

###### 

Patient characteristics and procedure data

  ------------------------------------------------------------------------------------------------------------------------------
                           All patients\         Classical LF-LG\          Paradoxical LF-LG\    NF-LG\                P value
                           (N=418)               (n=118, 28.2%)            (n=80, 19.1%)         (n=220, 52.6%)        
  ------------------------ --------------------- ------------------------- --------------------- --------------------- ---------
  Age, years               84.0 (81.0--87.0)     84.0 (80.0--87.0)         85.0 (82.0--88.0)     84.0 (81.0--87.0)     0.080

  Male                     136 (32.5)            48 (40.7)                 21 (26.3)             67 (30.5)             0.066

  BSA, m²                  1.42 (1.32--1.53)     1.43 (1.34--1.51)         1.41 (1.29--1.51)     1.43 (1.32--1.56)     0.600

  STS score, %             7.1 (4.9--10.0)       8.6 (5.4--13.5)†          7.4 (5.3--11.3)†      6.5 (4.8--9.1)        0.001

  Clinical frailty score   4.0 (3.0--5.0)        4.0 (3.0--5.0)            4.0 (3.0--4.0)        4.0 (3.0--5.0)        0.281

  NYHA 3 or 4              219 (52.4)            70 (59.3)                 41 (51.3)             107 (48.6)            0.170

  Angina                   70 (16.7)             25 (21.2)                 8 (10.0)              37 (16.8)             0.118

  Syncope                  45 (10.8)             10 (8.5)                  15 (18.8)             20 (9.1)              0.037

  Smoking                  101 (24.2)            29 (24.6)                 15 (18.8)             57 (25.9)             0.437

  DM                       143 (34.2)            44 (37.3)                 31 (38.8)             68 (30.9)             0.318

  Dyslipidaemia            183 (43.8)            47 (39.8)                 32 (40.0)             104 (47.3)            0.316

  Hypertension             335 (80.1)            94 (79.7)                 62 (77.5)             179 (81.4)            0.750

  CKD                      274 (65.6)            79 (66.9)                 60 (75.0)             135 (61.4)            0.083

  Atrial fibrillation      136 (32.5)            38 (32.2)                 33 (41.3)             65 (29.5)             0.160

  IHD                      182 (43.5)            61 (51.7)                 33 (41.3)             88 (40.0)             0.106

  PAD                      71 (17.0)             22 (18.6)                 20 (25.0)             29 (13.2)             0.047

  Stroke                   66 (15.8)             21 (17.8)                 9 (11.3)              36 (16.4)             0.438

  COPD                     92 (22.0)             25 (21.2)                 21 (26.3)             46 (20.9)             0.595

  BNP, pg/mL               215.4 (98.1--480.0)   558.3 (269.1--953.9)\*†   197.7 (89.4--346.4)   152.5 (71.1--287.4)   \<0.001

  Transapical approach     89 (21.3)             20 (16.9)                 21 (26.3)             48 (21.8)             0.281

  THV type                                                                                                             

   Sapien XT               346 (82.8)            94 (79.7)                 65 (81.3)             187 (85.0)            0.428

   CoreValve               28 (6.7)              15 (12.7)                 4 (5.0)               9 (4.1)               0.008

   Sapien 3                44 (10.5)             9 (7.6)                   11 (13.8)             24 (10.9)             0.373
  ------------------------------------------------------------------------------------------------------------------------------

Values are expressed as n (%), median (IQR).

\*P\<0.05 versus paradoxical LF-LG severe AS.

†P\<0.05 versus NF-LG severe AS.

AS, aortic stenosis;BNP, brain natriuretic peptide;BSA, body surface area;CKD, chronic kidney disease;COPD, chronic obstructive pulmonary disease;DM, diabetes mellitus;IHD, ischaemic heart disease;LF, low-flow;LG, low-gradient;NF, normal-flow; NYHA, New York Heart Association;PAD, peripheral artery disease;STS, Society of Thoracic Surgeons\' risk model;THV, transcatheter heart valve.

###### 

Echocardiography data

  ---------------------------------------------------------------------------------------------------------------------------
                        All patients\         Classical LF-LG\         Paradoxical LF-LG\     NF-LG\                P value
                        (N=418)               (n=118, 28.2%)           (n=80, 19.1%)          (n=220, 52.6%)        
  --------------------- --------------------- ------------------------ ---------------------- --------------------- ---------
  TTE (pre-TAVI)                                                                                                    

  AVA, cm^2^            0.71±0.15             0.67±0.15\*              0.63±0.14\*            0.76±0.13             \<0.001

  MG, mm Hg             32.4 (28.0--36.0)     31.6 (25.8--35.9)\*      30.5 (25.1--34.0)\*    33.8 (29.9--37.0)     \<0.001

  Vmax, m/s             3.80 (3.50--4.02)     3.68 (3.30--4.00)\*      3.70 (3.40--3.99)\*    3.88 (3.60--4.08)     \<0.001

  LVEF, %               60.7 (47.0--67.0)     39.0 (33.2--45.0)\*†     64.7 (60.3--68.0)      64.5 (58.8--70.7)     \<0.001

  SVi, mL/m^2^          39.7 (32.1--49.0)     36.4 (28.6--44.9)\*†     27.7 (24.8--31.7)\*    45.1 (39.7--53.4)     \<0.001

  LAD, mm               42.0±7.3              43.3±7.7                 41.2±7.0               41.6±7.1              0.071

  E/e′                  19.4 (14.6--24.3)     21.0 (15.5--28.0)\*      17.8 (13.9--25.5)      18.3 (14.3--23.0)     0.035

  Moderate-severe AR    36 (8.6)              20 (16.9)                4 (5.0)                12 (5.5)              0.001

  Moderate-severe MR    42 (10.0)             27 (22.9)                6 (7.5)                9 (4.1)               \<0.001

  Mean BP, mm Hg        106.3 (97.5--114.3)   101.7 (90.5--108.0)\*†   107.2 (100.3--115.4)   108.7 (98.5--117.7)   \<0.001

  LVEDV, mL             80.9 (62.3--107.5)    113.0 (91.3--142.0)\*†   59.0 (49.1--72.4)\*    74.6 (60.6--99.0)     \<0.001

  LVESV, mL             32.9 (20.1--53.9)     68.0 (51.0--88.9)\*†     21.0 (16.5--25.5)\*    26.0 (18.9--37.3)     \<0.001

  TTE (post-TAVI)                                                                                                   

  EOA, cm^2^            1.60 (1.35--1.90)     1.69 (1.40--1.98)\*      1.50 (1.25--1.70)†\*   1.63 (1.37--1.94)     0.001

  THV MG, mm Hg         8.5 (7.0--11.0)       8.00 (6.00--10.00)†      8.2 (6.3--11.0)        9.0 (7.0--11.9)       0.004

  LVEF, %               61.4 (51.4--67.5)     45.3 (38.2--53.0)\*†     63.9 (57.1--68.0)      65.1 (59.0--69.6)     \<0.001

  SVi, mL/m^2^          42.9 (34.6--53.0)     41.9 (33.4--52.0)\*†     34.3 (25.2--40.0)†     46.3 (38.6--55.7)     \<0.001

  E/e′                  19.1 (15.0--25.3)     19.5 (16.4--27.7)        17.8 (13.9--25.4)      19.4 (14.8--24.5)     0.264

  Moderate-severe PVL   6 (1.4)               3 (2.5)                  1 (1.3)                2 (0.9)               0.479

  Moderate-severe MR    33 (7.9)              16 (13.7)                5 (6.3)                12 (5.5)              0.024
  ---------------------------------------------------------------------------------------------------------------------------

Values are expressed as n (%), median (IQR) and mean±SD.

\*P\<0.05 versus NF-LG severe AS.

†P\<0.05 versus paradoxical LF-LG severe AS

AR, aortic regurgitation;AS, aortic stenosis;AVA, aortic valve area;BP, blood pressure; EOA, effective orifice area;E/e\', transmitral early peak velocity to early diastolic mitral annular tissue velocity; LAD, left atrial diameter;LF, low-flow;LG, low-gradient;LVEDV, left ventricular end-diastolic volume;LVEF, left ventricular ejection fraction;LVESV, left ventricular end-systolic volume;MG, mean pressure gradient;MR, mitral regurgitation;NF, normal-flow;PVL, paravalvular leakage;SVi, stroke volume index; TAVI, transcatheter aortic valve implantation;THV, transcatheter heart valve;TTE, transthoracic echocardiography; Vmax, max velocity.

Comparison of the three groups {#s3-2}
------------------------------

Classical low-flow low-gradient AS, paradoxical low-flow low-gradient AS and normal-flow low-gradient severe AS groups included 118 (28%), 80 (19%) and 220 (53%) patients, respectively ([figure 1](#F1){ref-type="fig"}). The normal-flow low-gradient AS group had significantly lower risk score as compared with the other groups as per the Society of Thoracic Surgeons' risk model. Baseline brain natriuretic peptide levels were significantly higher in the classical low-flow low-gradient AS group than that in the paradoxical low-flow low-gradient AS and normal-flow low-gradient severe AS groups. Patients who underwent the CoreValve procedure were most prevalent in the classical low-flow low-gradient AS group. Aortic valve area, mean gradient and maximum velocity of pre-TAVI were highest in the normal-flow low-gradient AS group. Left ventricular ejection fraction values before and after TAVI were lowest in the classical low-flow low-gradient AS group. Pre-TAVI and post-TAVI SVi were lowest in the paradoxical low-flow low-gradient AS group and lower in the classical low-flow low-gradient AS than in the normal-flow low-gradient AS group. Pre-TAVI and post-TAVI echocardiographic data showed that the incidence of moderate-severe mitral regurgitation was most prevalent in the classical low-flow low-gradient AS group ([table 1](#T1){ref-type="table"}).

Midterm clinical outcomes {#s3-3}
-------------------------

All-cause mortality rate during the follow-up period was 12.0%. Among these, the cardiovascular mortality rate was 4.1%. The mean follow-up period after TAVI was 9.2 months (IQR, 3.2--15.3) for the primary endpoint. The rate of hospitalisation for heart failure during follow-up (7.5, IQR, 3.2--14.0 months) was 11.1% (46 patients). Kaplan-Meier analysis showed no significant difference in the cardiovascular mortality (log-rank test p=0.245) and rate of hospitalisation for heart failure (log-rank test p=0.129) among the three groups ([figure 2](#F2){ref-type="fig"}).

![Kaplan-Meier curves for cardiovascular death rate and rate of hospitalisation for heart failure according to the type of LG AS. Survival rates for cardiovascular death (A) and hospitalisation for heart failure (B) were calculated using the Kaplan-Meier method and compared using the log-rank test. No significant differences were observed among the three LG groups. AS, aortic stenosis; LF, low-flow; LG, low-gradient; NF, normal-flow.](openhrt-2018-000988f02){#F2}

Change between pre-TAVI and post-TAVI echocardiography {#s3-4}
------------------------------------------------------

SVi significantly improved after TAVI in the classical low-flow low-gradient AS group and paradoxical low-flow low-gradient AS group (classical low-flow low-gradient AS group, 36.4 mL/m[@R2] (IQR, 28.6--44.9) vs 41.9 mL/m[@R2] (IQR, 33.4--52.0), p\<0.001; paradoxical low-flow low-gradient AS group, 27.7 mL/m[@R2] (IQR, 24.8--31.7) vs 34.3 mL/m[@R2] (IQR, 25.2--40.0), p\<0.001) ([figure 3A](#F3){ref-type="fig"}). Left ventricular ejection fraction significantly improved after TAVI in the classical low-flow low-gradient AS group (39.0% (IQR, 33.2--45.0) vs 45.3% (IQR, 38.2--53.0), p\<0.001) ([figure 3B](#F3){ref-type="fig"}).

![Comparison of echocardiographic parameters before and after TAVI. (A) SVi significantly improved after TAVI in patients with classical and paradoxical LF-LG severe AS, but not in those with HF-LG severe AS. (B) LVEF improved only in patients with classical LF-LG severe AS. AS, aortic stenosis; LF, low-flow; LG, low-gradient; LVEF, left ventricular ejection fraction; NF, normal-flow; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation.](openhrt-2018-000988f03){#F3}

Predictors of clinical outcomes {#s3-5}
-------------------------------

The predictors of primary and secondary outcomes are shown in [tables 3 and 4](#T3 T4){ref-type="table"}. The independent predictor of cardiovascular mortality during follow-up was post-TAVI SVi (per 10 mL/m[@R2] decrease) (HR, 2.00; 95% CI 1.28 to 3.12; p=0.002). The adjusted values for all parameters are shown in [table 3](#T3){ref-type="table"}. In addition, the independent predictors of the rate of hospitalisation for heart failure are post-TAVI SVi (per 10 mL/m[@R2] decrease) (HR, 1.35; 95% CI 1.03 to 1.76; p=0.028), pre-TAVI mitral valve regurgitation grade 3 or 4 (HR, 2.71; 95% CI 1.26 to 5.82; p=0.011) and baseline natriuretic peptide levels of the brain (per 100 pg/mL increase) (HR, 1.06; 95% CI 1.01 to 1.11; p=0.025). The adjusted values for all parameters are shown in [table 4](#T4){ref-type="table"}.

###### 

Predictors of cardiovascular death

                                           HR     Univariate           Multivariate                         
  ---------------------------------------- ------ -------------------- -------------- ------ -------------- -------
  Age (per 1-year increase)                1.01   0.92 to 1.10         0.880                                
  Male                                     0.66   0.22 to 2.03         0.471                                 
  NYHA class 3 or 4                        0.09   0.87 to 7.00         0.091                                 
  DM                                       1.33   0.51 to 3.50         0.560                                 
  Dyslipidaemia                            0.67   0.25 to 1.81         0.429                                 
  Hypertension                             1.34   0.38 to 4.65         0.650                                 
  CKD                                      7.56   1.00 to 57.1         0.050                                 
  Atrial fibrillation                      1.21   0.45 to 3.28         0.706                                 
  PAD                                      2.58   0.95 to 6.97         0.062                                 
  COPD                                     0.70   0.41 to 3.84         0.698                                 
  BNP, pg/mL (per 100 pg/mL increase)      1.00   0.92 to 1.09         0.968                                 
  STS score (per 1 U increase)             1.04   1.00 to 1.07         0.030                                 
  Transapical approach                     1.13   0.37 to 3.47         0.832                                 
  TTE (pre-TAVI)                                                                                             
  LAD, mm (per 1 mm increase)              1.03   0.97 to 1.09         0.375                                 
  AVA, cm^2^ (per 0.1 cm^2^ decrease)      1.06   0.76 to 1.47         0.725                                 
  MG, mm Hg (per 10 mm Hg decrease)        0.56   0.28 to 1.15         0.117                                 
  SVi, mL/m^2^ (per 10 mL/m^2^ decrease)   1.42   0.91 to 2.23         0.123                                 
  LVEF, % (per 10% decrease)               1.06   0.76 to 1.48         0.720                                 
  Moderate-severe AR                       0.04   0.00 to 63.79        0.399                                 
  Moderate-severe MR                       2.17   0.62 to 7.56         0.226                                 
  TTE (post-TAVI)                                                                                            
  EOA, cm^2^ (per 0.1 cm^2^ decrease)      0.92   0.81 to 1.05         0.223                                 
  MG, mm Hg (per 10 mm Hg decrease)        0.64   0.15 to 2.67         0.536                                 
  SVi, mL/m^2^ (per 10 mL/m^2^ decrease)   1.98   1.31 to 2.99         0.001          2.00   1.28 to 3.12   0.002
  LVEF, % (per 10% decrease)               1.24   0.87 to 1.76         0.230                                 
  Moderate-severe PVL                      0.05   0.00 to 6.56×10^6^   0.752                                 
  Moderate-severe MR                       1.61   0.37 to 7.06         0.527                                 

AR, aortic regurgitation; AVA, aortic valve area; BNP, brain natriuretic peptide; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EOA, effective orifice area; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; MG, mean pressure gradient; MR, mitral regurgitation; NYHA, New York Heart Association; PAD, peripheral artery disease; PVL, paravalvular leakage; STS, Society of Thoracic Surgeons\' risk model; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TTE, transthoracic echocardiography.

###### 

Predictors of hospitalisation for heart failure

                                           Univariate   Multivariate                                 
  ---------------------------------------- ------------ -------------- ------- ------ -------------- -------
  Age (per 1-year increase)                1.03         0.97 to 1.10   0.279                         
  Male                                     1.32         0.72 to 2.40   0.372                          
  NYHA class 3 or 4                        1.17         0.66 to 2.09   0.595                          
  DM                                       1.15         0.63 to 2.09   0.650                          
  Dyslipidaemia                            0.72         0.40 to 1.31   0.289                          
  Hypertension                             1.93         0.82 to 4.56   0.133                          
  CKD                                      1.63         0.83 to 3.21   0.159                          
  Atrial fibrillation                      1.70         0.94 to 3.06   0.077                          
  PAD                                      1.74         0.90 to 3.37   0.098                          
  COPD                                     1.38         0.71 to 2.67   0.338                          
  BNP pg/mL (per 100 pg/mL increase)       1.04         1.00 to 1.07   0.038   1.06   1.01 to 1.11   0.025
  STS score (per 1 U increase)             1.03         1.00 to 1.06   0.022                          
  Transapical approach                     1.52         0.80 to 2.89   0.199                          
  TTE (pre-TAVI)                                                                                      
  LAD, mm (per 1 mm increase)              1.04         1.00 to 1.08   0.043                          
  AVA, cm^2^ (per 0.1 cm^2^ decrease)      0.96         0.78 to 1.17   0.672                          
  MG, mm Hg (per 10 mm Hg decrease)        1.68         1.08 to 2.61   0.020                          
  SVi, mL/m^2^ (per 10 mL/m^2^ decrease)   1.25         0.96 to 1.63   0.094                          
  LVEF, % (per 10% decrease)               1.23         1.02 to 1.50   0.033                          
  Moderate-severe AR                       0.22         0.03 to 1.62   0.054                          
  Moderate-severe MR                       2.97         1.47 to 5.99   0.002   2.71   1.26 to 5.82   0.011
  TTE (post-TAVI)                                                                                     
  EOA, cm^2^ (per 0.1 cm^2^ decrease)      1.06         0.99 to 1.15   0.111                          
  MG, mm Hg (per 10 mm Hg decrease)        2.89         1.11 to 7.46   0.029                          
  SVi, mL/m^2^ (per 10 mL/m^2^ decrease)   1.47         1.16 to 1.87   0.001   1.35   1.03 to 1.76   0.028
  LVEF, % (per 10% decrease)               1.30         1.05 to 1.61   0.015                          
  Moderate-severe PVL                      1.60         0.22 to 11.6   0.642                          
  Moderate-severe MR                       2.40         1.08 to 5.38   0.033                          

AR, aortic regurgitation; AVA, aortic valve area; BNP, brain natriuretic peptide; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; EOA, effective orifice area; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; MG, mean pressure gradient; MR, mitral regurgitation; NYHA, New York Heart Association; PAD, peripheral artery disease; PVL, paravalvular leakage; STS, Society of Thoracic Surgeons\' risk model; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TTE, transthoracic echocardiography.

Analysis of receiver operating characteristic curve {#s3-6}
---------------------------------------------------

Pairwise comparison of receiver operating characteristic curves showed that post-TAVI SVi presented a significantly larger area under the curve than pre-TAVI SVi for the prediction of cardiovascular mortality (0.61 (95% CI 0.56 to 0.65) vs 0.74 (95% CI 0.69 to 0.78), p=0.012). A post-TAVI SVi threshold of \<41.4 mL/m[@R2] was obtained from the receiver operating characteristic curves to predict cardiovascular mortality (sensitivity, 88.2%; specificity, 55.6%) ([figure 4](#F4){ref-type="fig"}).

![Receiver operating characteristic curves of pre-TAVI and post-TAVI SVi for predicting cardiovascular mortality. Youden Index indicated that the optimal cut-off levels of SVi to predict cardiovascular mortality was 41.4 mL/m^2^. Post-TAVI SVi shows significantly larger AUC than pre-TAVI SVi for the prediction of cardiovascular mortality. AUC, area under the curve; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation.](openhrt-2018-000988f04){#F4}

Discussion {#s4}
==========

The main findings are as follows: (1) Post-TAVI SVi is an independent predictor of cardiovascular mortality and rate of hospitalisation for heart failure after TAVI in patients with low-gradient severe AS. (2) Post-TAVI SVi is a better predictor of cardiovascular mortality than pre-TAVI SVi in patients with low-gradient severe AS. (3) Kaplan-Meier analysis showed no significant difference in cardiovascular mortality and rate of hospitalisation for heart failure among the three low-gradient AS groups in this study. (4) Finally, SVi improved after TAVI in the classical and paradoxical low-flow low-gradient severe AS groups, but not in the normal-flow low-gradient severe AS group.

TAVI improved left ventricular function, and the improvement in left ventricular ejection fraction was the predictor of a good prognosis in patients with severe AS who presented with reduced left ventricular ejection fraction.[@R11] However, Le Ven *et al* [@R15] reported that left ventricular ejection fraction underestimates myocardial systolic dysfunction in cases with concentric remodelling. This confirmed our results that left ventricular ejection fraction was not a predictor of cardiovascular mortality and rehospitalisation for heart failure.

Prior reports showed that pre-TAVI SVi is a powerful independent predictor of all-cause or cardiovascular mortality, and SVi is a better predictor of a left ventricular ejection fraction prognosis in patients with severe AS.[@R3] The present study showed that post-TAVI SVi, not pre-TAVI, is an independent predictor of cardiovascular mortality and rehospitalisation for heart failure. Pairwise comparison of receiver operating characteristic curves also showed that post-TAVI SVi was a better predictor of cardiovascular mortality and rehospitalisation for heart failure than pre-TAVI SVi. The utility of post-TAVI SVi might be because it was influenced by the baseline characteristics and by the effect of TAVI itself.

In our study, Kaplan-Meier analysis showed no significant difference among the three low-gradient groups in cardiovascular mortality and hospitalisation for heart failure. This was not consistent with our prior reports and other reports describing that normal-flow low-gradient severe AS had a better outcome compared with paradoxical low-flow low-gradient severe AS.[@R3] It was considered that there were possibilities that our study population was too small and/or had too short of a follow-up period to produce a significant difference.

In the present study, a post-TAVI SVi threshold of \<41.4 mL/m[@R2] was obtained from the receiver operating characteristic curves to predict the cardiovascular mortality, higher than that of pre-TAVI SVi (35 mL/m[@R2]), as defined by the guideline and reported by our previous study.[@R3] The patients with low-flow in this study had an increased SVi after TAVI, and naturally the cut-off value was higher than that before TAVI. This suggests that we should carefully consider the patients who show low-flow status (SVi \<35 mL/m[@R2]) and low-normal-flow status (35≤SVi\<40 mL/m[@R2]) after TAVI.

There are five limitations to our study. First, this was a retrospective analysis of data that were collected prospectively. Second, we did not use core laboratory analysis. The technical inaccuracy and facility disparity of the Doppler echocardiographic measurement of SVi and the mean gradient cannot be ruled out. Third, a small number of events and short-term follow-up, which may limit statistical power, were considered in this study. We selected and analysed the variables using a stepwise (forward selection) method for Cox proportional hazards multivariable regression models to analyse the set of variables in this model.[@R21] A larger study with a longer follow-up is strongly needed to confirm these results. Fourth, we did not exclude the five cases of death within 30 days after the procedure, which were procedure-related events. All patients in this study underwent post-TAVI echocardiography, which implied that the intraoperative deaths and deaths immediately after the TAVI procedure were excluded. This could overcome the potential bias of some patients with a clinically probable poor prognosis undergoing echocardiography sooner than other patients. Moreover, post-TAVI echocardiography could exclude at least the earlier events related to the procedure. Finally, we did not measure afterload parameters, such as valvuloarterial impedances both before and after TAVI, which are also considered as prognostic markers after TAVI.

Conclusions {#s5}
===========

SVi measured after TAVI is an independent predictor of cardiovascular mortality in patients with low-gradient severe AS and is a better prognostic marker compared with preprocedure findings. Our results suggest that clinicians should evaluate SVi in patients with low-gradient severe AS before and after TAVI, and patients with low-flow status, especially with low-normal-flow status after TAVI, should be subjected to a stricter follow-up protocol.
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